🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK Β· Real-Time Price Β· USD
50.78
-0.68 (-1.32%)
At close: Nov 20, 2026, 4:00 PM EST
52.48
+1.70 (3.35%)
After-hours: Nov 20, 2026, 7:38 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

MYQORZO's launch is exceeding expectations, while MAPLE-HCM supports earlier treatment consideration. A 2027 nHCM expansion could double the addressable market, with slower titration and real-world evidence shaping use and REMS discussions.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Alrighty. Getting my steps in and also risking getting hit by a cab, but that is part of the job description here. I really do appreciate it. My name's Akash Tewari. I lead our pharma and biotech research efforts here at Jefferies. I have the pleasure of hosting the Cytokinetics management team. Obviously a very important launch going on in the HCM space with MYQORZO. Robert, why don't I hand it off to you for intro remarks, and we'll get started.

Robert Blum
President and CEO, Cytokinetics

Thank you. Thanks for inviting us back. Yesterday, we made an announcement that the FDA has approved our supplemental NDA, and therefore has expanded the label for MYQORZO for inclusion of results from MAPLE-HCM, a study of monotherapy MYQORZO versus monotherapy metoprolol. At this conference, we've been talking about how that's informative, and as we guided, not per se transformative. It's instead incremental, but step one towards a multi-step process to ensure that those results can be not only distinguishing aficamten from mavacamten, but more importantly, activating more physicians to be considering use of a cardiac myosin inhibitor earlier in the treatment of patients with oHCM. Until such time as the guidelines are updated, which we expect to occur both in Europe and in the U.S. next year, we think physicians will more likely be still needing to step through beta blockers, but may do so more rapidly.

That physician behavior over time will contribute to changes in how payers perceive this category. We do believe that that will be meaningfully important over the longer term to be enabling of more cardiologists, especially in the community, who follow guidelines to be more comfortable starting patients sooner, or instead of on a beta blocker. So, that's the news as it relates to yesterday's announcement and MAPLE-HCM. Put that into the context of what we've already been reporting with our Q3 earnings call recently. The MYQORZO launch is off to a very good start. We're exceeding expectations, not just in the things that relate to the obvious net sales exceeding consensus, but also the things we've pointed to in terms of breadth and depth of prescribing and category growth, all of which are meaningfully different now year-over-year for the addition of aficamten into this marketplace.

We're very encouraged by everything we're seeing towards those objectives. Lastly, we guided that we're going to be submitting this quarter the sNDA for ACACIA, and as could be enabling of the expansion of the label yet again next year to be inclusive of not only oHCM, but nHCM. That represents a potential doubling in the TAM, and where we think MYQORZO could ultimately be the leader in this space. We think that's distinguishing because MYQORZO would then be the only cardiac myosin inhibitor approved across the full spectrum of HCM obstructive and non-obstructive. So, 2026 is proving to be a very good year. We were reflecting a moment ago about how a year ago, we were being asked questions like, "Why do you have confidence that aficamten will be approved in oHCM?

Why do you think that you could be approved with a differentiated risk mitigation profile? Why do you think you can compete effectively with BMS in a market where they've already been present for four years? We think we're executing very well against all of those, and as we peer into 2027, even more ambitious plans ahead.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Understood. Let's start on the commercial side, and I know your team's very conservative, and that's just good hygiene, I would say, in general. Let's push you a bit on this, because it's funny, you had almost the identical number of days for the first quarter of MYQORZO, first quarter of CAMZYOS. I'm looking at quarter-over-quarter performance. You are 2.5 x better than where CAMZYOS was at the same time point. I know your team previously said, "Look, we hope to be better than what the CAMZYOS launch was," but that was an aspiration, but not something that we could really look and point to hard numbers on. Number two, you get MAPLE, and then we're going to get non-obstructive, and we'll talk a bit about that as well. You're already on a faster run rate in terms of patient adds.

Why would we not see patient adds accelerate over the next, let's say, year, as you get the MAPLE indication and non-obstructive put on the label? What's the right run rate to think about for MYQORZO patient adds as we get out to the end of the decade?

Robert Blum
President and CEO, Cytokinetics

We talk about velocity. By definition, we do believe that there should be an acceleration of patient adds. I think more important in the medium to long term is how is this category growing?

And where is that growth coming from, and to what extent can we capture that? BMS isn't going to lie down, but I do think that BMS is investing in ways that will serve both companies well. They're activating more community cardiologists who had been previously not writing a cardiac myosin inhibitor. We're focusing, as we indicated we would, to those high-volume accounts. At one time, they represented 80% of the business, now maybe closer to 60% of the business at the present quarter. But we do think this augurs well for BMS and Cytokinetics to continue to do well and even better over time, so accelerating. To your question about, if I'm hearing you correctly, how might that contribute to something that's less linear and more asymmetric, I do think that one should be pointing to when do we really bend the curve?

I do think that could be conceivable in 2027, especially with the add of nHCM.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Right. Let's put it another way, and that's quite helpful color. It's not fun to deal with this with the twin goals of launch curves, but often cardiovascular companies will remind us, it takes some time, maybe years two to three is when we start to see an inflection. You talked about bending the curve. Do you feel like the evidence you've seen so far with the CAMZYOS launch, I mean, sorry, the MYQORZO launch, this is not like a traditional CV launch that we've seen. We are seeing uptake rapidly out of the gate, and it's at a different cadence than what maybe investor, what we saw with CAMZYOS, where it did take a couple years to really get the system wired.

Robert Blum
President and CEO, Cytokinetics

Ours is next in the marketplace. It's next in class, if you will. Traditional cardiology launches, a second entrant into the category does see uptake sooner. But to the point of, is it a non-classical cardiovascular launch? I think it's too early to say that.

I think it could very well track with other cardiology launches. The nice thing about cardiology launches is there's a long tail. You saw it with Entresto, and everybody remembers how people were questioning whether Novartis was going to be able to achieve its sales guidance, and they blew through it and doubled it over time. Folks were questioning whether CAMZYOS could be a $4 billion drug at peak, and therefore, did BMS pay too much in acquiring it when they guided to $4 billion? I think they're on track to do $4 billion at peak, and I think we'll hopefully do better.

I think this is tracking like you should expect a cardiovascular launch to track.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Understood. When we think about non-obstructive HCM, and you're going to have an approval decision on that from the agency sometime next year, talk to me about your confidence of the data that you did generate, in terms of, A, getting approval, but then B, it does seem like your team thinks there is a bolus, that there are patients who are waiting to get treatment. A, comments on approval, B, has your team identified patients who would immediately be seeking treatment with MYQORZO when this does get onto the market?

Robert Blum
President and CEO, Cytokinetics

Let me ask Fady to answer the first and Andrew maybe to answer the second.

Fady Malik
EVP of Research and Development, Cytokinetics

Sure. The ACACIA data were really solid. Both endpoints were met. The data are consistent through the secondary endpoints. There is no meaningful heterogeneity in the secondary endpoints. It is serving a patient population that has no alternative therapies.

First time we have seen a medical therapy be effective, or any therapy be effective in nHCM. We are high. Our confidence is high. Nothing is 100%, but our confidence is high that this drug should make it through an approval and to patients, especially as it is a supplemental indication, right? Aficamten is already on the market. It is already out there. This represents an extension of its use into an adjacent population, and generally, the medical need is what guides, what usually guides regulatory authorities.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Understood.

Andrew Callos
EVP and Chief Commercial Officer, Cytokinetics

Now w e've done, and just maybe just on the uptake. We have done extensive promotion, discussion with physicians, and those that are experienced CMI users, which are several hundred, they do have patients warehoused. They are waiting for this approval. They are anticipating it. They are telling us they are motivated, they are intending it to use on New York Heart Association Class II, III. We are expecting in that segment an accelerated launch versus what we saw in oHCM.

Overall, I think the launch will be similar than when you look at outside of that segment of experienced CMI users.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Okay, wait. I just want to put that to a finer point. You think the launch, in terms of additional patient adds, will look similar to obstructive?

Andrew Callos
EVP and Chief Commercial Officer, Cytokinetics

Outside of those experienced CMIs, yes.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Okay. Interesting. Now, it's one of the When we do a KOL call, and I remember when the data was top line, and it's like, "Oh, well, it's a three-point KCCQ." Then you show them the curve where, well, it actually, you measured two other points, and now it's five. But there is an element, like your team doesn't just sit pat on data. You publish a lot of phase IV studies, long-term follow-ups, and I do think the non-obstructive HCM data package is going to become more robust as we get into next year. But that's an initial wall. We'll hear from docs like, "Hey, I'm not sitting here blown away with a three-point KCCQ score." That's the initial perception on maybe top-line data. You guys have now gotten to the field, you've talked to doctors, and you've also shown people some of the curves.

What do you think the perception will be as we go into next year and beyond, and what are some longer-term data sets that we should be anticipating that could really inform the robustness of your efficacy package?

Robert Blum
President and CEO, Cytokinetics

Yeah, perhaps I can start, then maybe Fady, but I want to maybe just clarify for the folks in the room. The change from baseline for patients on aficamten was over 10 points. While relative to placebo that saw some wobble at 36 weeks, it was on average, five to seven points greater on aficamten than placebo. But at one time point, it was three-ish points. The difference, however, to point out is that these patients are coming in with a baseline, and then over 24, 36 weeks, they're experiencing huge benefits in terms of relief of symptoms. That's what's ultimately going to guide physician behavior and how they might adopt a new medicine in a disease where there is no approved treatment.

They're not going to focus on whether it was three points at 36 weeks or five points at another. They're going to focus on how their patients are coming back feeling a whole lot better. Relative to their own baseline, it's a massive difference. So too did placebo patients do better, but placebo isn't subject to a regulatory review.

In this case, we would be. I do believe that'll drive adoption in the marketplace. Maybe if you want to add.

Fady Malik
EVP of Research and Development, Cytokinetics

Yeah. I think it is a difference in terms of speaking with physicians that participated in the trial and those that didn't. If you speak to the physicians that had patients in the study, that enrolled patients, that had patients in the open label, they're very compelled by what they see. It underlies how our tools to measure patient improvement are relatively still crude. They underestimate often what patient benefits are. You talk to physicians that have had no experience with patients, they look at the numbers and they may be more or less convinced based on whether they look at the totality of the evidence or they focus on one data point. I think I tend to trust the physicians that have experience with the drug. That's, I think, what increases my conviction in terms of the meaningfulness of these data.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Understood. Maybe just lastly on nHCM. I think one thing that is fair is, we've seen with multiple CMIs, you do have a higher LVEF drop rate. You have to dose up more. We'll get into the whole decouple discussion in a bit. There is this dynamic of educating doctors on how to use this drug in nHCM is important, thinking about background medication in a way that maybe wasn't as necessary in obstructive. First of all, do you agree with that? Then number two, what are you doing from a patient support perspective? What are you doing from a physician education perspective to make sure there is this kind of seamless transition? Then how do we think about label changes as non-obstructive data gets onto the label?

Fady Malik
EVP of Research and Development, Cytokinetics

Well, I think there is a little bit of aβ€”t here's certainly a difference between the obstructive and non-obstructive patients in terms of burden of disease at baseline. In ACACIA, there was more fibrosis, their ejection fractions are lower at baseline.

In general, the patients are sicker at baseline, a bit older and so forth. What we did in ACACIA, we followed the dosing cadence that we did in SEQUOIA, in the oHCM trial, and that was probably a mistake in the sense that these patients probably should be titrated more gently, more slowly. In the open-label extension FOREST, that was the case. There was no forced titration every two weeks. They could titrate every two to six weeks. Titration was under control of the physician as opposed to a computer. They could therefore integrate other signs of improvement or things that might cause them to slow down. We saw a rate of heart failure that was about 1% in the patients that were naive to aficamten. I think education falls along the lines of treating this more like a heart failure drug.

We start beta blockers in heart failure patients. Physicians are very used to start, go slow, evaluate the patient, and so forth. It is not new for them, but we just have to make that connection for them in terms of how to use aficamten in that setting. Labeling, beta blockers are labeled for heart failure. There is some guidance in the label that suggests that patient evaluation is important during dose escalation and treatment. There are means, there is precedent, if you will, for providing that kind of guidance.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Okay. This is quite important. Sounds like you are having a discussion when you are thinking about non-obstructive, where you are like, "Look, we ran this titration because we had an endpoint, we had a dose we wanted to get to." It does not sound like that is exactly the language you want on titration on the label, right?

Fady Malik
EVP of Research and Development, Cytokinetics

Yeah.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

What flexibility do you have, because you do have long-term follow-up data from FOREST, to maybe get that incorporated? I do not think investors necessarily appreciate this.

Fady Malik
EVP of Research and Development, Cytokinetics

Well, I think in SEQUOIA, we did an every two-week titration. The label allows for titration within a two to eight-week window.

So, it provides greater flexibility. That is in the open-label extension, it's essentially how patients are treated. So, there is precedent, if you will, for applying what we're doing in the open-label extension. I don't think anyone wants to force anybody to dose anything faster than it needs to be. So, the label will very likely reflect what's ongoing now in the open-label extension. And it provides greater flexibility to physicians as well.

Robert Blum
President and CEO, Cytokinetics

Akash, I also want to comment on something you said about dose titration and getting to doses and requiring higher doses.

If you look at the EXPLORER data as it relates to mavacamten and the real-world experience with mavacamten, patients are seemingly maintained on substantially lower doses. Same is true if you look at SEQUOIA data and real-world evidence of aficamten. A majority of patients today on aficamten, over half of them are on 5 mg and maintained at 5 mg. Another 30% are on 10 mg and maintained on 10 mg. So, it seems that in real world, physician behavior would dictate that patients seem to be doing just fine on doses at the lower end of the dose response curve without having to necessarily push everybody to 15 mg or 20 mg. And I think in nHCM, it stands to reason that physicians may also be comfortable starting patients on 5 mg, see how they're doing.

Are they symptom burden relief or are they not? And maybe just leave them there, and that would be just fine.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Yeah.

Robert Blum
President and CEO, Cytokinetics

That reads on the number of echoes, by the way, too, which I'm sure you're going to get to.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Actually, let's get to that. I think that's the first time you said. 80% of patients are on that 5 mg and 10 mg dose in the real world. I remember doing KOL work. That was a big question people had is like, "Oh, did I have to dose up?" What does that actually translate into number of echoes that we're seeing in the real world with MYQORZO versus CAMZYOS? Because I know there was always this kind of pushback, "Well, docs are used to the old way, and they're not going to adopt." Even though there is dosing flexibility, even though there might be less echoes possible with MYQORZO, they'll revert to the mean. Have you seen a shift in terms of physician outlook here with that?

Robert Blum
President and CEO, Cytokinetics

Let me ask Andrew to comment, please.

Andrew Callos
EVP and Chief Commercial Officer, Cytokinetics

I mean, the window, to your point, there's a wide use of the window, two to eight weeks. It's more on average, more like a five-week timeframe, five and a half. So they're taking longer. Some of that is just convenience in terms of scheduling. Some of it is they want to go slower with dosing. But we are seeing a wide window. And the 50%, I mean, there's over 1,000 patients we have now on maintenance when we looked a few months ago, and the 80% of that are in 5 mg and 10 mg are what Robert kind of defined.

When we talked about nHCM to physicians, we did some pretty extensive research, and they told us the same thing. They're going to take their time.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Right.

Andrew Callos
EVP and Chief Commercial Officer, Cytokinetics

They're not going to go like they do in a clinical trial. We'll sign up speakers, and we'll educate peer-to-peer. We'll educate with reps. We'll educate with our medical colleagues. It'll likely be the same REMS system. It'll be same dosing. So there's familiarity, and I think that's why the experienced CMI users that I talked about earlier said, they have warehouse patients, and they plan on using it, and they're pretty excited about the possibility.

Robert Blum
President and CEO, Cytokinetics

But Andrew, to his question about the number of echoes if patients in oHCM are 5 mg and 10 mg.

Andrew Callos
EVP and Chief Commercial Officer, Cytokinetics

Two. You start on 5 mg, you get an echo. If the echo is confirmed, then you stay on 5 mg, six months later, for most patients, it is two echoes.

If you reach 10 mg, it is one more echo in that year, three echoes.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Right.

Andrew Callos
EVP and Chief Commercial Officer, Cytokinetics

We are at two or three echoes, not including a baseline echo that any product would have. Two to three echoes a year for 5 mg and 10 mg for 80% of patients.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Just remind us, in terms of cost savings, because that is often not always covered. That might be an out-of-pocket expense. What does that mean to the patient in terms of what they are spending to get on the rightβ€”

Andrew Callos
EVP and Chief Commercial Officer, Cytokinetics

Echoes are covered because they're part of a drug use utilization. It's a very low copay in Medicare. We can provide copay assistance in commercial. That has not been an issue for coverage, echo.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Okay. Understood. I can't help but look at your SEQUOIA data. You had, okay, so 80% of your patients right now in the real world are well treated on 5 mg and 10 mg. If you look at your titration for SEQUOIA, I think 1.3% of patients had any LVEF mandated titration adjustment. If I look at just your 5 mg and 10 mg dose, the number is zero. You had zero LVEF reductions on what seems like your actual dose. So, there's this paradigm of we're going to symptomatic titration, symptomatic treatment. Is that actually already happening? How are patients even choosing to go on a higher dose today from a physician perspective? Are they looking at the obstruction, or are they really looking at NYHA class? Are they looking at KCCQ?

Akash Tewari
Analyst, Jefferies

I'll bridge that into kind of a larger discussion of maybe that's getting already treated in the real world. When can the FDA maybe remove a REMS or really go to a symptomatic dosing paradigm?

Fady Malik
EVP of Research and Development, Cytokinetics

Yeah, I mean, physicians, to push dose are often guided by a residual gradient.

They want to treat the gradient, and even if patients feel better, if there is gradient still 70, they do not really like people hanging around at that. That might be motivation to push the dose. I think what you are seeing in the majority use of 5 mg and 10 mg is that many of these patients, their gradients are resolving with 5 mg and 10 mg. Symptoms are resolving, and they are feeling fine to stand pat there. I think that is a, as you said, the risk, if you want to call that, is even lower because of the lower doses that are being applied. In SEQUOIA, you did not see much. In the REMS program, we are seeing excellent safety from what we have seen so far.

As to relaxing the REMS, the FDA likes to see real-world data, and the nice thing about a launch that is adding thousands of patients a year is that very soon we will have 10,000 patient years of data.

In a couple years, we can go back and say, "We think these things could be either eliminated or relaxed." What is the trade-off between burden and benefit? If the safety profile continues to be as good as we are observing, the burden becomes really the driving factor there in that decision.

Robert Blum
President and CEO, Cytokinetics

But to your point, at 5 mg and 10 mg, there is, for a majority of patients, you heard us say 80% of patients are treated on 5 mg to 10 mg, there is no evidence in SEQUOIA or otherwise that these patients are having any EF excursions. So you could imagine a scenario by which there is a relaxing of the REMS for a large cross-section of the patients.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Understood. I'll sneak in one more, and I always try to get a more cheeky question at the end. You entertain me. I think sometimes we see, and Robert, you've told us, "Hey, the only people who seem to think this way are investors. When I talk to doctors, when I talk to strategics, they have no idea that this is even a thing," right? Some of these narratives just don't extend actually when we get into physician discussions or strategic discussions. I can't help but think people would say, "Hey, we know how many patients are on 5 mg and 10 mg. We probably have a sense that you can remove a REMS after showing actual data and having a productive discussion with the agency." There is an investor perception that, hey, one of the companies that's behind you won't require echoes, and that's considered differentiated.

When you get into strategic discussions or discussions with doctors, is that narrative true when we get to those stakeholders?

Robert Blum
President and CEO, Cytokinetics

I think history would teach us that it's very risky to go into a phase III study with a protocol and assume that that equals a label, and that in a category where there's already a REMS, one would expect for a drug that has the same risk of systolic dysfunction, a removal of a REMS absent real-world evidence. I don't think that's lost on cardiologists or potential strategics.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Understood. Last question for you. There's been a show-me element to the HCM market, even going back to Bristol. What do you feel like you have to kind of prove at this point? You hit on non-obstructive, you have MAPLE, the launch is going well. Where do you feel like, "I still feel like I'm hitting this wall of skepticism"?

Robert Blum
President and CEO, Cytokinetics

I think we are in the middle.

There is BMS, and then there are two companies that are following us maybe four to five years later, and it contributes to a stirring of the pot where there are multiple incentives associated with how the Street might view these different companies. We are just executing on our business. We continue to demonstrate we can exceed expectations, and we are focused heads down on the things we can control. Everything else will take care of itself, and I think in time, we continue to show that the things we say we can do, we are doing.

If anything, we are exceeding those expectations. Ultimately, we are a company of 28 years. We are accustomed to dealing with skepticism and overcoming obstacles, and here we are, I think, a resilient, persistent company that will continue to do the right thing by the business and shareholders.

Akash Tewari
Global Head of Biopharmaceutical Research, Jefferies

Understood. Okay. Thank you so much.